Article
Defining cellular determinants of resistance to PD-1 pathway blockade in non-small-cell lung cancer
2024-06-09
Abstract excerpt
<h4>Summary</h4> Despite sustained clinical responses to immune-checkpoint blockade (ICB) therapies in non-small-cell lung cancer (NSCLC), the majority of patients derive no clinical benefits, and the cellular and molecular underpinnings of such resistance remain incompletely understood. To identify cell types that may influence immunotherapy responses, we first integrated newly generated and previously published...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 19563abe-0de2-5478-aeec-a2cdc6d89189
- DOI
- 10.1101/2024.06.06.597777
